Comparative Pharmacology
Head-to-head clinical analysis: ADVIL LIQUI GELS versus MEFENAMIC ACID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADVIL LIQUI GELS versus MEFENAMIC ACID.
ADVIL LIQUI-GELS vs MEFENAMIC ACID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis and thereby decreasing inflammation, pain, and fever.
Reversible inhibition of cyclooxygenase (COX-1 and COX-2) leading to decreased prostaglandin synthesis; exhibits both central and peripheral analgesic effects.
200–400 mg orally every 4–6 hours as needed; maximum 1200 mg/day.
500 mg orally as an initial dose, followed by 250 mg every 6 hours as needed, not to exceed 1 week.
None Documented
None Documented
1.8 to 2.5 hours. The short half-life supports dosing every 4 to 6 hours for acute pain and fever.
Clinical Note
moderateMefenamic acid + Gatifloxacin
"Mefenamic acid may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderateMefenamic acid + Rosoxacin
"Mefenamic acid may increase the neuroexcitatory activities of Rosoxacin."
Clinical Note
moderateMefenamic acid + Levofloxacin
"Mefenamic acid may increase the neuroexcitatory activities of Levofloxacin."
Clinical Note
moderateMefenamic acid + Trovafloxacin
Terminal half-life is 2-4 hours; prolonged in hepatic impairment and overdose.
Renal excretion of metabolites and conjugates accounts for approximately 90% of an administered dose. Less than 1% is excreted unchanged. Biliary/fecal elimination accounts for about 10%.
Primarily renal (52% as glucuronide metabolites, <6% unchanged) and fecal (20-30% via biliary elimination).
Category C
Category D/X
NSAID
NSAID
"Mefenamic acid may increase the neuroexcitatory activities of Trovafloxacin."